Grand Pharmaceutical’s Innovative Ophthalmic Product Gains Macao Approval

Grand Pharmaceutical Group Limited ( (HK:0512) ) just unveiled an announcement.

Grand Pharmaceutical Group Limited announced that its innovative ophthalmic product, GPN01768, has been approved for commercialization by the Pharmaceutical Administration Bureau of Macao, China. This approval is expected to pave the way for further approvals in the Guangdong-Hong Kong-Macao Greater Bay Area and Mainland China, addressing the urgent clinical need for effective treatment of Demodex blepharitis, a common ophthalmic disease. The company has made significant progress in its research and development pipeline, aiming to strengthen its position in the ophthalmology sector and expand its market presence with a series of innovative products.

More about Grand Pharmaceutical Group Limited

Grand Pharmaceutical Group Limited is a company focused on the pharmaceutical industry, particularly in the field of ophthalmology. It is dedicated to the innovation and development of ophthalmic drugs, with a strategic emphasis on treating conditions such as myopia, dry eye, pterygium, and Demodex blepharitis. The company has established a comprehensive product system and a professional marketing team to enhance its market competitiveness.

Average Trading Volume: 23,792,453

Technical Sentiment Signal: Buy

Current Market Cap: HK$32.62B

Learn more about 0512 stock on TipRanks’ Stock Analysis page.